The global cartilage repair market size was valued at USD 2.63 billion in 2025 and is projected to grow from USD 2.77 billion in 2026 to USD 4.16 billion by 2034, registering a CAGR of 5.23% during the forecast period (2026–2034). North America dominated the cartilage repair market with a share of 47.69% in 2025.
Cartilage repair refers to medical procedures, techniques, and biomaterials used to restore, regenerate, or replace damaged cartilage, particularly articular cartilage in joints. Cartilage repair products are tracked under HSN Code 9021 (orthopedic appliances and artificial parts of the body) and SIC Code 3841 (surgical and medical instruments and apparatus).
The cartilage repair market demand is driven by the prevalence of cartilage-related joint disorders, increasing traumatic cartilage injuries, growing adoption of minimally invasive orthopedic procedures, and development of regenerative medicine technologies. Orthopedic healthcare providers are increasingly adopting implants, scaffolds, cell-based approaches, and other repair technologies, contributing to cartilage repair market growth.
By Treatment Modality
By Application Site
By Application
By End User
Download a Free Sample To learn more about this report,
Expansion of Off-the-Shelf Cartilage Repair Implants
The cartilage repair market analysis shows that the need for simpler and faster treatment is supporting ready-to-use cartilage repair implants that do not require patient-specific manufacturing. These products can be stored and prepared before surgery, helping reduce treatment delays and simplify the clinical process. This shift is broadening access to standardized cartilage repair solutions.
Development of Cell-Free Cartilage Regeneration Technologies
The focus on biological tissue restoration is supporting implants that stimulate the body's own repair processes without using cultured cells. These technologies use scaffolds or bioactive materials to support new cartilage formation at the damaged site. This development is creating alternative regenerative approaches for cartilage repair.
Supply chain disruptions are expected to have a substantial impact on the cartilage repair market share, as dependence on specialized biomaterials, collagen membranes, scaffolds, sterile manufacturing, and qualified production facilities can create material shortages, procurement delays, and interruptions in product availability. The market is likely to follow a capacity-constrained recovery pattern, as demand for cartilage repair remains supported by joint injuries and regenerative treatment needs while limited availability of specialized materials, qualified suppliers, and manufacturing capacity can restrict the pace at which certain products return to full supply. The market is expected to grow at a CAGR of 5.23%, but supply chain constraints could approximately lower this by 0.5 percentage points, resulting in short-term growth of around 4.73%. As supply conditions normalize through broader supplier qualification, improved biomaterial availability, expanded manufacturing capacity, and more reliable medical device logistics, cartilage repair market growth is expected to gradually return to 5.23%.
The cartilage repair market forecasts investments directed toward advanced regenerative medicine technologies, tissue-engineered scaffolds, cell-based therapies, and minimally invasive cartilage repair solutions to address unmet needs in joint preservation.
Key Investment and Funding Activities in the Cartilage Repair Market, 2025–2026
Lamina Therapeutics
USD 11.6 million Series A financing
In June 2026, Lamina Therapeutics opened a USD 11.6 million Series A financing round to fund European Phase I/II clinical development of Lamina.One, a minimally invasive regenerative therapy designed to simultaneously restore subchondral bone and cartilage.
Nanochon
USD 4.1 million in Seed Prime II funding
In January 2026, Nanochon secured USD 4.1 million in Seed Prime II funding, bringing its total capital raised to USD 11.3 million. This supports its first-in-human clinical study for an implant designed to treat articular cartilage defects, while advancing R&D and manufacturing capabilities.
Regentis Biomaterials
USD 10 million through an initial public offering
In December 2025, Regentis Biomaterials raised USD 10 million through an initial public offering, with approximately USD 8.1 million in net proceeds allocated to advance its pivotal Phase III trial and commercialization preparation for GelrinC, an off-the-shelf hydrogel implant for knee cartilage repair.
Prevalence of Osteoarthritis and Sports Injuries Drives Cartilage Repair Market Demand
The higher prevalence of osteoarthritis is increasing the number of patients experiencing cartilage deterioration, joint pain, and reduced mobility. Progressive damage can create a need for procedures that restore or protect affected joint surfaces. This growing disease burden is strengthening demand for knee cartilage repair and other orthopedic treatments.
A greater incidence of sports-related injuries is increasing the number of patients with cartilage damage caused by impact, repetitive stress, or joint trauma. Active individuals often seek treatments that can support mobility and return to activity. The rising demand for sports medicine is therefore creating more opportunities for joint repair procedures.
Reimbursement Limitations and Strict Regulatory Compliance Restrain Market Expansion
Limited reimbursement for regenerative cartilage treatments can reduce patient access to newer procedures such as autologous chondrocyte implantation (ACI) and other advanced therapies. Inconsistent coverage can increase out-of-pocket expenses and make treatment less affordable. This situation can reduce procedure volumes and slow adoption across healthcare systems.
Complex regulatory compliance requirements can increase the effort and resources needed to commercialize innovative cartilage implants and biomaterial-based solutions. Manufacturers may need to meet detailed requirements related to clinical evidence, product safety, quality systems, and manufacturing standards. Greater regulatory complexity can therefore make market entry more difficult for smaller manufacturers and new technologies.
Development of 3D-Printed Implants and Combination Therapies Create Growth Opportunities for Cartilage Repair Market Players
The development of 3D-printed cartilage implants can enable more precise implant structures for individual cartilage defects. Advanced printing methods can support complex shapes and porous designs using biomaterials. Greater design flexibility can create differentiated products for joint repair. This technology can open new commercial opportunities for customized orthopedic solutions.
The combination therapies can bring together biological agents, scaffolds, and other treatment approaches to improve cartilage healing. These therapies can create new options for patients with different levels of cartilage damage. Greater use of combined approaches can expand applications in regenerative medicine. This can also create opportunities for new treatment platforms and product partnerships.
Limited Availability of Advance Equipment and Long Manufacturing Lead Times Challenge Market Growth
Advanced cartilage repair procedures can require specialized surgical instruments and equipment that may not be available in smaller orthopedic facilities. Limited access to these resources can prevent some centers from offering newer cartilage regeneration procedures. This can concentrate treatment in larger hospitals and specialty centers. Uneven facility readiness can therefore limit market reach across regions.
Long manufacturing lead times and delays in obtaining suitable biomaterials can affect the timely production of cartilage repair products. Supply interruptions may postpone deliveries and create inventory gaps for healthcare providers. These delays can make it harder for manufacturers to respond quickly to changing demand.
The cell-based cartilage repair segment accounted for a share of 31.42% in 2025, supported by the use of cartilage-forming cells to regenerate damaged articular cartilage. Established techniques such as autologous chondrocyte implantation support its leading position in the treatment of localized cartilage defects.
The stem cells segment is expected to grow at a CAGR of 8.21% during the forecast period, driven by continued development of regenerative approaches using stem cells for cartilage restoration.
Request Customizationto receive a tailored report.
The hyaline cartilage segment is expected to grow at a CAGR of 5.61% during the forecast period, supported by the clinical need to restore the smooth, load-bearing cartilage found at joint surfaces.
The fibrocartilage segment is expected to grow at a CAGR of 4.42% during the forecast period, supported by cartilage repair procedures that stimulate bone marrow cells to form fibrocartilage within damaged areas.
The knee cartilage repair segment accounted for a share of 61.48% in 2025, owing to the high clinical need for treating localized cartilage defects in the knee.
The ankle and foot segment is expected to grow at a CAGR of 5.12% during the forecast period, driven by the use of cartilage repair procedures for localized defects and osteochondral lesions in the ankle and foot.
The hospital segment accounted for a share of 58.42% in 2025, supported by the specialized surgical infrastructure and orthopedic expertise required for cartilage repair procedures. The availability of advanced imaging, rehabilitation, and postoperative care strengthens the role of hospitals in cartilage repair treatment.
The ambulatory surgical centers segment is expected to grow at a CAGR of 6.12% during the forecast period, propelled by the use of minimally invasive cartilage procedures that can be performed in outpatient settings.
Speak to an Analystto discuss market opportunities.
Market Dominance Supported by FDA-Cleared Implants and
The North America cartilage repair market accounted for the largest regional share of 47.69% in 2025, supported by strong adoption of cartilage repair implants, advanced orthopedic treatment centers, and ongoing development of regenerative approaches.
The U.S. cartilage repair market benefits from the availability of FDA-cleared cartilage repair and osteochondral implants. This supports the broader use of structural repair solutions for knee cartilage defects. The FDA has also approved a resorbable implant for repairing knee cartilage and osteochondral lesions.
The Canada cartilage repair market is boosted by the development of biomaterials designed for cartilage repair and regeneration, creating a stronger foundation for cartilage therapies. In 2026, a Canadian clinical trial began evaluating the Nanochon Chondrograft implant for the surgical treatment of knee cartilage lesions.
Unlock Regional Insightsto access country-level data, & regional trends.
Fastest Growth Fueled by Research Efforts and Booming Medical Device Sector
The Asia Pacific cartilage repair market is expected to grow at a CAGR of 7.34% during the forecast period, supported by next-generation cartilage regeneration adoption and focus on diagnosing localized cartilage injuries.
The Japan cartilage repair market growth is supported by government-backed research into iPS-cell-derived cartilage and regenerative treatments. Japan’s AMED selected an Osaka University project developing iPS-cell-derived cartilage for knee injuries, supporting next-generation cartilage regeneration.
The China cartilage repair market is fueled by the development of 3D-printed grafts for focal knee cartilage defects, creating opportunities for patient-specific repair solutions. Nanchang University is funding a clinical trial in China to assess 3D-printed transplants for knee cartilage damage.
The India cartilage repair market is shaped by the booming medical device sector, which is projected to reach USD 30–50 billion within this decade. This supports rising healthcare demand and greater adoption of advanced medical technologies, creating a favorable environment for cartilage-repair implants and regenerative orthopedic technologies.
Market Expansion Led by Established Specialist Pathways and Established Use of Cell-based Therapies
The Europe cartilage repair market is expected to grow at a CAGR of 4.91% during the forecast period, supported by increasing adoption of autologous chondrocyte implantation and strong cartilage regeneration R&D.
The NHS has established specialist pathways for cartilage transplantation and autologous chondrocyte implantation, leading to sustained growth of the UK cartilage repair market. This enables access to advanced repair procedures for focal knee cartilage defects. NHS England has also commissioned fresh osteochondral allografts for osteochondral lesions of the knee, supporting clinical use of cartilage-repair technologies.
Germany’s cartilage repair market is supported by established clinical use of cell-based therapies, with data from the German Cartilage Registry showing autologous chondrocyte implantation (ACI) accounted for 52.4% of recorded knee cartilage repair procedures among 5,143 patients. Germany’s G-BA has formally recognized matrix-associated autologous chondrocyte implantation for symptomatic knee cartilage damage.
Market Growth Led by Stem Cell Research and Biologic Treatment Development
The Latin America cartilage repair market is expected to grow at a CAGR of 5.18% during the forecast period, supported by increasing use of biological cartilage-repair techniques and growing research into tissue regeneration approaches. In 2025, Brazilian Fluminense Federal University examined mesenchymal stem cells specifically for knee cartilage defects, supporting continued development of the stem cell therapy approach. Mexico’s growing burden of musculoskeletal disorders is increasing interest in minimally invasive biological approaches for cartilage and joint damage.
Market Ecosystem Reshaped by Advanced Healthcare Frameworks
The Middle East & Africa cartilage repair market is expected to grow at a CAGR of 4.76% during the forecast period, supported by development in non-cell-based cartilage repair and cell-free composites. The UAE's medicine framework is creating opportunities for scaffold-based cartilage repair approaches, where the Dubai Health Authority issued regenerative-medicine standards recognizing bone marrow-derived MSCs and platelet-rich plasma (PRP) for cartilage repair. In August 2025, South African researchers at the University of the Witwatersrand developed a stimuli-responsive hydrogel for intra-articular therapy in osteoarthritis.
The cartilage repair market competitive landscape is moderately concentrated, with participation from orthopedic medical-device manufacturers, sports medicine companies, regenerative medicine specialists, tissue engineering developers, and biologics-focused healthcare firms. Key players such as Zimmer Biomet Holdings, Inc., Stryker Corporation, Smith & Nephew plc, Arthrex, Inc., and Vericel Corporation are collectively estimated to account for approximately 35–40% of the global cartilage repair market share.
Established participants compete primarily through implant and scaffold technology, clinical evidence, regulatory approvals, portfolio breadth, and global distribution capabilities. Emerging, niche, and regional companies in the cartilage repair market ecosystem compete through cell-based therapies, minimally invasive procedures, biomaterials, and specialized solutions targeting specific cartilage defects and patient populations.
April 2026: Smith+Nephew reported five-year randomized clinical-trial data for its CARTIHEAL AGILI-C cartilage repair implant.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Latin America Diabetes Devices Market Size & Trends by 2034
Middle East And Africa Diabetes Devices Market Size and Forecast 2034
North America Diabetes Devices Outlook, Growth, Report to 2033
Home Healthcare Devices Market Size, Share, Growth, Analysis, Report, 2034
Europe Diabetes Devices Market Size & Trends by 2034
Asia Pacific Diabetes Devices Market Size & Trends by 2034
We are featured on:
sales@straitsresearch.com